A Comparison of Medial and Lateral Temporal Lobe Atrophy in Dementia with Lewy Bodies and Alzheimer’s Disease: Magnetic Resonance Imaging Volumetric Study

2001 ◽  
Vol 12 (3) ◽  
pp. 198-205 ◽  
Author(s):  
R. Barber ◽  
I.G. McKeith ◽  
C. Ballard ◽  
A. Gholkar ◽  
J.T. O’Brien
1999 ◽  
Vol 29 (1) ◽  
pp. 181-187 ◽  
Author(s):  
G. T. HARVEY ◽  
J. HUGHES ◽  
I. G. McKEITH ◽  
R. BRIEL ◽  
C. BALLARD ◽  
...  

Background. Temporal lobe atrophy on magnetic resonance imaging (MRI) has been suggested as a specific diagnostic marker for Alzheimer's disease (AD). No previous comparison with dementia with Lewy bodies (DLB) has been reported.Method. T1-weighted MRI scans were performed on 11 subjects with AD (nine with NINCDS/ADRDA probable AD and two with neuropathologically proven AD) and nine subjects with DLB (four with probable DLB diagnosed by clinical criteria and five with neuropathologically proven DLB). Groups were matched for age, duration of illness and cognitive test score. Two raters, blind to diagnosis and neuropathological findings, measured the volumes of the frontal lobes, temporal lobes, hippocampi, parahippocampal gyri, amygdalae, and caudate nuclei using a computerized volumetric analysis system. Scans were also rated for medial temporal atrophy on a four-point scale by an experienced rater.Results. AD subjects had significantly smaller left temporal lobes and parahippocampal gyri than those with DLB. Medial temporal atrophy was present in 9/11 AD cases (82%) and absent in 6/9 (67%) of DLB cases. Two neuropathologically confirmed cases of DLB had severe medial temporal atrophy; both had concurrent AD-type pathology in the temporal lobe (Braak stage 4).Conclusions. This pilot study supports the hypothesis that a greater burden of pathology centres on the temporal lobes in AD compared with DLB, except in DLB cases with concurrent Alzheimer pathology. A larger study is needed to confirm these findings and to determine whether MRI has a role in assisting with the clinical differentiation between DLB and AD.


Author(s):  
U Saeed ◽  
P Desmarais ◽  
M Masellis

Background: The ɛ4-allele of apolipoprotein E (APOE-ɛ4) increases the risk not only for Alzheimer’s disease (AD), but also for Parkinson’s disease dementia and dementia with Lewy bodies (collectively, Lewy body dementia [LBD]). Hippocampal volume is an important neuroimaging biomarker for AD and LBD, although its association with APOE-ɛ4 is inconsistently reported. We investigated the association of APOE-ε4 with hippocampal atrophy quantified using magnetic resonance imaging in AD and LBD. Methods: Electronic databases (PubMed, Embase, PsycINFO, Scopus, Web of Science) were systematically searched for studies published up until December 31st, 2020. Results: Thirty-nine studies (25 cross-sectional, 14 longitudinal) were included. We observed that: (1) APOE-ε4 was associated with greater rate of hippocampal atrophy in AD and those who progressed from mild cognitive impairment to AD, (2) APOE-ε4 carriers showed greater involvement of cornu ammonis-1 hippocampal subfield versus non-carriers in AD, (3) APOE-ɛ4 may influence hippocampal atrophy in dementia with Lewy bodies, although longitudinal investigations are required, and (4) APOE-ε4 associated with earlier rather than very late expression of mediotemporal degeneration and memory-related neurocognitive impairment. Conclusions: The role of APOE-ɛ4 in modulating hippocampal phenotypes may be further clarified through more homogenous, well-powered, pathology-proven studies. Understanding the underlying mechanisms will facilitate development of prevention strategies targeting APOE-ɛ4.


Sign in / Sign up

Export Citation Format

Share Document